NXTCHealthcare · BiotechnologyNXTC Stock Forecast: NextCure, Inc. Price Predictions for 2026-2027
The 3 Wall Street analysts covering NextCure, Inc. hold a median 12-month price target of $20 — +354.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
NXTC stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores NextCure, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (89): Smaller than most of the companies we track.
Value (11): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own NextCure, Inc. — and when they’d sell — is the membership.
NXTC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NXTC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +354.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 May 2026 | LUCID CAPITAL MARKETS | Initiates | Buy | $25 |
| 7 Nov 2025 | Ladenburg Thalmann | Upgrade | Buy | — |
| 15 July 2025 | Piper Sandler | Maintains | Overweight | — |
| 1 July 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Aug 2024 | Needham | Reiterates | Buy | — |
| 3 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 May 2024 | Needham | Reiterates | Buy | — |
| 22 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 Mar 2024 | Needham | Maintains | Buy | — |
| 14 Dec 2023 | Needham | Maintains | Buy | — |
| 8 Aug 2023 | HC Wainwright & Co. | Initiates | Buy | — |
| 4 Aug 2023 | Needham | Reiterates | Buy | — |
| 5 May 2023 | Needham | Reiterates | Buy | — |
| 3 Mar 2023 | Needham | Reiterates | Buy | — |
| 4 Nov 2022 | Ladenburg Thalmann | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NXTC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
NextCure, Inc. (NXTC) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.2×
- Price / sales
- —
- Price / book
- 0.6×
- EV / EBITDA
- 0.2×
Cheaper than 77% of US stocks
Cheaper than 83% of US stocks
Cheaper than 60% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −132.4%
- Return on assets
- −66.7%
- Dividend yield
- —
Higher than 10% of US stocks
Higher than 5% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
NXTC vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NXTC appears on the weeks it earns a place.
Frequently asked questions about NXTC stock
What is the NXTC stock price forecast for 2026-2027?
The 3 Wall Street analysts covering NextCure, Inc. have a median 12-month price target of $20, with estimates ranging from $15 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is NXTC stock a buy right now?
Of the 3 analysts covering NextCure, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NextCure, Inc. 37 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank NXTC?
As at 1 Aug 2026, NextCure, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).
Will NXTC stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +354.5% from the last close, and Ticker Nerd's factor model ranks NextCure, Inc. 37 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the NXTC stock forecast for 2030?
No analyst covering NextCure, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NXTC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $25 over the next 12 months.
How has NXTC stock performed over the past year?
NextCure, Inc. returned -10.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does NextCure, Inc. do?
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunomedicines for cancer and other immune-related diseases.
About NextCure, Inc.
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunomedicines for cancer and other immune-related diseases. Headquartered in Beltsville, Maryland, the company concentrates on therapies designed to restore normal immune function rather than broadly suppress or stimulate the immune system. NextCure’s pipeline includes product candidates such as NC410, a fusion protein targeting the LAIR pathway being evaluated in combination with established oncology treatments, and LNCB74, an antibody-drug conjugate directed at the B7-H4 cancer target. The company also advances additional clinical and preclinical programs addressing both oncology and non-oncology indications, including chronic bone diseases and neurodegenerative conditions. Operating within the biotechnology segment of the healthcare sector, NextCure collaborates selectively with partners to progress certain programs, while leveraging its discovery capabilities to identify new immunomodulatory targets. Its activities contribute to the broader immuno-oncology and immune-disease treatment landscape by aiming to provide differentiated, mechanism-based therapeutic options for patients with significant unmet medical needs.
CEO Mr. Michael S. Richman MSBA · 40 employees · United States · https://www.nextcure.com